PRME
Price
$2.98
Change
-$0.01 (-0.33%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
521.46M
28 days until earnings call
Intraday BUY SELL Signals
TNXP
Price
$8.89
Change
-$0.34 (-3.68%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
169.8M
38 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PRME vs TNXP

PRME vs TNXP Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PRME vs. TNXP commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and TNXP is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
PRME vs TNXP: Fundamental Ratings
PRME
TNXP
OUTLOOK RATING
1..100
5351
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
8088
P/E GROWTH RATING
1..100
10059
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TNXP's Valuation (12) in the Pharmaceuticals Other industry is in the same range as PRME (32) in the null industry. This means that TNXP’s stock grew similarly to PRME’s over the last 12 months.

TNXP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as PRME (100) in the null industry. This means that TNXP’s stock grew similarly to PRME’s over the last 12 months.

PRME's SMR Rating (95) in the null industry is in the same range as TNXP (98) in the Pharmaceuticals Other industry. This means that PRME’s stock grew similarly to TNXP’s over the last 12 months.

PRME's Price Growth Rating (80) in the null industry is in the same range as TNXP (88) in the Pharmaceuticals Other industry. This means that PRME’s stock grew similarly to TNXP’s over the last 12 months.

TNXP's P/E Growth Rating (59) in the Pharmaceuticals Other industry is somewhat better than the same rating for PRME (100) in the null industry. This means that TNXP’s stock grew somewhat faster than PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMETNXP
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
82%
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (PRME: $2.99 vs. TNXP: $9.23)
Brand notoriety: PRME and TNXP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 86% vs. TNXP: 97%
Market capitalization -- PRME: $521.46M vs. TNXP: $169.8M
PRME [@Biotechnology] is valued at $521.46M. TNXP’s [@Biotechnology] market capitalization is $169.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 1 FA rating(s) are green while TNXP’s FA Score has 1 green FA rating(s).

  • PRME’s FA Score: 1 green, 4 red.
  • TNXP’s FA Score: 1 green, 4 red.
According to our system of comparison, TNXP is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 4 TA indicator(s) are bullish while TNXP’s TA Score has 4 bullish TA indicator(s).

  • PRME’s TA Score: 4 bullish, 5 bearish.
  • TNXP’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, PRME is a better buy in the short-term than TNXP.

Price Growth

PRME (@Biotechnology) experienced а -2.61% price change this week, while TNXP (@Biotechnology) price change was -4.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

PRME is expected to report earnings on Oct 30, 2026.

TNXP is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
PRME
Daily Signal:
Gain/Loss:
TNXP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LQDH92.66-0.01
-0.01%
iShares Interest Rate Hedged Corporate Bond ETF (LQDH)
IBGB22.24-0.04
-0.18%
iShares iBonds Dec 2045 Term Treasury ETF (IBGB)
KTEC11.73-0.06
-0.48%
KraneShares Hang Seng TECH Index ETF (KTEC)
YDEC27.66-0.19
-0.68%
FT Vest International Equity Moderate Buffer ETF - December (YDEC)
EMLC24.53-0.30
-1.21%
VanEck J. P. Morgan EM Local Currency Bond ETF (EMLC)

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been closely correlated with CRSP. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-2.13%
CRSP - PRME
69%
Closely correlated
+0.22%
BEAM - PRME
66%
Loosely correlated
-0.25%
RXRX - PRME
65%
Loosely correlated
-1.45%
EDIT - PRME
63%
Loosely correlated
-1.95%
NTLA - PRME
58%
Loosely correlated
+0.50%
More

TNXP and

Correlation & Price change

A.I.dvisor indicates that over the last year, TNXP has been closely correlated with ICU. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if TNXP jumps, then ICU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TNXP
1D Price
Change %
TNXP100%
-5.24%
ICU - TNXP
77%
Closely correlated
-4.82%
RXRX - TNXP
42%
Loosely correlated
-1.45%
DNLI - TNXP
40%
Loosely correlated
-0.68%
ABSI - TNXP
40%
Loosely correlated
-0.19%
PRME - TNXP
39%
Loosely correlated
-2.13%
More